[Clinical study of transurethral surgery for benign prostatic hyperplasia using a thick loop (VaporTome)]

Area of Science:

• Urology
• Minimally Invasive Surgery

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Symptomatic BPH significantly impacts quality of life and urinary function.
• Traditional treatments like transurethral resection of the prostate (TURP) carry risks and costs.

Purpose of the Study:

• To evaluate the efficacy and safety of transurethral surgery using VaporTome for symptomatic BPH.
• To assess the impact of VaporTome on International Prostate Symptom Score (IPSS), quality of life (QoL), peak flow rate (PFR), prostate volume, and residual urine.

Main Methods:

• A prospective study involving 23 patients with symptomatic BPH.
• Transurethral surgery was performed using a VaporTome device.
• Clinical outcomes were assessed at 1, 3, 6, and 12 months post-operation.

Main Results:

• Significant reductions in mean IPSS (22.6 to 5.3), QoL index (5.5 to 1.2), prostate volume (66.9 to 18.2 ml), and residual urine (167.9 to 20.4 ml).
• Significant increase in mean PFR (6.2 to 17.4 ml/sec).
• High overall efficacy rates: 80.9% at 1 month, peaking at 94.7% at 6 months, and 85.8% at 12 months. No serious complications were reported.

Conclusions:

• Transurethral surgery with VaporTome is an effective and safe treatment for symptomatic BPH.
• The procedure offers advantages of high efficacy, minimal morbidity, and potentially lower costs compared to TURP and other minimally invasive options.